Every Form 4 that REGENXBIO Inc. (RGNX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow RGNX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RGNX filings page.
REGENXBIO Inc. (RGNX) reported that Chief Technology Officer Craig Malzahn had 234 shares of common stock disposed of on September 1, 2026 to satisfy tax withholding obligations upon the vesting of previously granted restricted stock units. The shares were valued at $9.32 per share for this tax calculation, and Malzahn now directly holds 81,960 shares of REGENXBIO common stock.
REGENXBIO Inc. (RGNX) reported that Chief Financial Officer Mitchell Chan had 4,902 shares of common stock withheld on September 1, 2026 to pay tax liabilities arising from the vesting of restricted stock units originally granted on September 16, 2024. The shares were valued at $9.32 per share, based on the issuer’s closing price that day, and reflect a tax-withholding disposition rather than an open-market sale. Following this event, Chan directly holds 122,815 shares of REGENXBIO common stock. No Rule 10b5-1 trading plan is reported for this transaction.
REGENXBIO Inc. (RGNX) director Gregory Austin Ciongoli reported multiple equity transactions. He purchased 49,196 shares of common stock on August 26, 2026 at a weighted average price of $9.1411 per share in open-market trades, and 53,407 shares on August 27, 2026 at a weighted average price of $9.3560 per share in open-market trades.
On August 25, 2026, he also received an equity compensation package consisting of 15,432 shares of time-based restricted stock units that vest in three equal annual installments on August 25, 2027, 2028 and 2029, and a stock option for 69,609 shares of common stock at an exercise price of $8.91 per share, vesting one-third on August 25, 2027 and the remainder in equal monthly installments over the following 24 months.
REGENXBIO Inc. Chief Medical Officer Steve Pakola reported a tax-withholding disposition of 7,468 shares of common stock on August 1, 2026, at $9.69 per share. The shares were withheld to cover taxes on vesting restricted stock units granted August 1, 2024. He now directly holds 205,541 shares.
REGENXBIO Inc. executive Patrick J. Christmas, Chief Strategy & Legal Officer, reported a tax-withholding disposition of 4,699 shares of common stock on August 1, 2026 at $9.69 per share. The shares were withheld to cover taxes on vesting RSUs granted August 1, 2024, leaving him with 205,968 shares held directly. The transaction was not made under a Rule 10b5-1 trading plan.
REGENXBIO Inc. Chief Executive Officer Simpson Curran reported routine equity compensation activity in company stock. On December 31, 2025, Curran acquired 951 shares of common stock at $6.9955 per share through the Employee Stock Purchase Plan (ESPP) for the July 1–December 31, 2025 purchase period, exempt under Rule 16b-3(c).
On June 30, 2026, Curran acquired an additional 1,453 shares at $10.18 per share via the ESPP for the January 1–June 30, 2026 purchase period. In line with the ESPP, these shares were bought at 85% of the relevant closing prices. On July 1, 2026, 6,818 shares were withheld at $13.09 per share to cover taxes upon vesting of restricted stock units granted on July 1, 2024, a non-market, tax-withholding disposition. After these transactions, Curran directly owned 338,053 shares of REGENXBIO common stock.
REGENXBIO Inc. Chief Medical Officer Steve Pakola exercised stock options and sold shares in a planned transaction. On this Form 4, he exercised options for 2,161 shares of common stock at $7.86 per share, then sold 2,161 shares in an open-market sale at $13.64 per share.
These transactions were made pursuant to a Rule 10b5-1 trading plan, indicating they were pre-scheduled. After the sale, he directly holds 213,009 shares of common stock and 64,812 stock options that remain exercisable.
REGENXBIO Inc. Chief Medical Officer Steve Pakola reported exercising stock options for 36,725 shares of common stock at $7.8600 per share on July 1, 2026, then selling 36,725 shares at $12.8600 the same day and 19,608 shares at $11.0400 on June 29, 2026.
After these trades he directly holds 213,009 shares of common stock, and 66,973 stock options from the reported award remained outstanding. Footnotes state that at least one transaction was effected under a Rule 10b5-1 trading plan, that some sales were executed in multiple trades at weighted-average prices between $11.00 and $11.18, and that a previously granted option for 103,698 shares vests 25% on January 2, 2026 with the balance in equal monthly installments over 36 months while he continues in service.
REGENXBIO Inc. director Daniel Tasse reported new equity awards. He received 9,807 shares of common stock through a time-based restricted stock unit grant, which will vest in full on May 29, 2027 if he remains in continuous service.
He was also granted stock options for 46,600 shares of common stock at an exercise price of $7.01 per share, vesting on May 29, 2027 and expiring on May 29, 2036. Following these awards, he directly holds 28,861 shares of common stock. These are compensation-related grants, not open-market purchases or sales.
REGENXBIO Inc. director David C. Stump reported equity compensation awards, not open-market purchases. He received 9,807 shares of common stock underlying a time-based restricted stock unit that will vest on May 29, 2027, subject to his continuous service to the company.
He was also granted stock options covering 46,600 shares of common stock at an exercise price of $7.01 per share, which vest on May 29, 2027 and expire on May 29, 2036. Following these awards, he holds 28,861 shares of common stock directly.
REGENXBIO Inc. director Jennifer Zachary reported equity awards from the company. She received 9,807 shares of common stock in the form of a time-based restricted stock unit award that will fully vest on May 29, 2027, subject to continued service. Following this grant, she directly holds 31,871 common shares. She was also granted stock options covering 46,600 shares of common stock at an exercise price of $7.01 per share, which will vest on May 29, 2027 and expire on May 29, 2036.
REGENXBIO Inc. director Kenneth T. Mills reported equity awards consisting of restricted stock units and stock options. On May 29, 2026, he received 9,807 shares of common stock through a time-based restricted stock unit award that carries no cash exercise price. These RSUs are scheduled to vest 100% on May 29, 2027, conditioned on his continuous service to the company. On the same date, he was also granted stock options covering 46,600 shares of common stock at an exercise price of $7.01 per share, which are likewise scheduled to vest on May 29, 2027, subject to continued service. Following the stock grant, Mills directly held 495,925 shares of REGENXBIO common stock.
REGENXBIO Inc. director George V. Migausky reported equity awards that increase his stake in the company. He received 9,807 shares of common stock as a time-based restricted stock unit award that will fully vest on May 29, 2027, contingent on continued service. Following this award, he directly holds 28,861 common shares. He was also granted stock options for 46,600 shares of common stock at an exercise price of $7.01 per share, which vest on May 29, 2027 and expire on May 29, 2036. These are compensation-related grants rather than open-market purchases or sales.
REGENXBIO Inc. director Argeris N. Karabelas received new equity awards as part of his compensation. He was granted 9,807 shares of common stock through a time-based restricted stock unit award that will fully vest on May 29, 2027, provided he continues to serve the company.
He also received stock options for 46,600 shares of common stock at an exercise price of $7.01 per share. These options begin vesting in 12 equal monthly installments after May 29, 2027 and expire on May 29, 2036. Following the RSU grant, he directly owns 28,861 shares of REGENXBIO common stock.
REGENXBIO Inc. reported that director Alexandra Glucksmann received new equity awards. She was granted 9,807 shares of Common Stock in the form of a time-based restricted stock unit award, which will vest 100% on May 29, 2027 if she continues service with the company.
She was also granted stock options covering 46,600 shares of Common Stock at an exercise price of $7.01 per share. These options will vest on May 29, 2027 and expire on May 29, 2036. Following the grants, she directly holds 28,861 Common Stock shares and 46,600 options. These are compensation awards rather than open-market purchases or sales.
REGENXBIO Inc. director Allan M. Fox reported new equity awards and updated indirect holdings. He received 9,807 shares of common stock as a time-based restricted stock unit grant, with all shares scheduled to vest on May 29, 2027, subject to continuous service.
He was also granted stock options for 46,600 shares at an exercise price of $7.01 per share, vesting on May 29, 2027 and expiring on May 29, 2036. Following these grants, he directly holds 28,861 common shares.
The filing also lists indirect holdings of common stock through entities including Quaker Gray LLC with 1,529,981 shares, HBF Gift Trust LLC with 315,000 shares, AMF Gift Trust LLC with 315,000 shares, and AMF Family Gift Trust LLC with 722,485 shares, with beneficial ownership of these indirect positions disclaimed except for his indirect pecuniary interest.
REGENXBIO Inc. director Jean Bennett received new equity awards as part of compensation. She was granted 9,807 shares of common stock in the form of a time-based restricted stock unit (RSU) award, bringing her total direct holdings to 28,861 common shares.
She was also granted stock options covering 46,600 shares of common stock at an exercise price of $7.01 per share. Both the RSU and the option award are scheduled to vest on May 29, 2027, subject to her continuous service with REGENXBIO. The options expire on May 29, 2036.
REGENXBIO Inc. Chief Medical Officer Steve Pakola reported an open-market sale of 15,309 shares of common stock on May 11, 2026 at a weighted average price of $11.02 per share. The transaction was executed under a Rule 10b5-1 trading plan, and he continues to hold 232,617 shares directly.
REGENXBIO Inc. Chief Medical Officer Steve Pakola reported an open-market sale of 5,124 shares of common stock at $10.35 per share. After this transaction, he directly holds 247,926 shares. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan, indicating it was scheduled in advance as part of routine portfolio management.
REGENXBIO Inc. Chief Strategy & Legal Officer Patrick J. Christmas reported a routine tax-related share withholding. On February 1, 2026, 4,700 shares of common stock were withheld at $11.16 per share to cover taxes on vesting restricted stock units. After this transaction, he beneficially owned 210,667 shares of REGENXBIO common stock directly.
REGENXBIO Inc. Chief Medical Officer reports tax share withholding. On February 1, 2026, 5,267 shares of REGENXBIO common stock were withheld at $11.16 per share to cover taxes due on the vesting of restricted stock units originally granted on August 1, 2024.
After this transaction, the reporting officer directly beneficially owned 253,050 shares of REGENXBIO common stock. The transaction was coded "F," indicating a tax-related withholding tied to equity compensation rather than an open-market trade.
REGENXBIO Inc. director Kenneth T. Mills reported exercising stock options for 225,000 shares of common stock on January 27, 2026 at an exercise price of $13.09 per share. These options were originally granted in 2016 and had fully vested prior to exercise.
To cover the option exercise price and related taxes, 221,753 shares of common stock were withheld by the company at a reference price of $13.41 per share, and the filing states there was no open-market sale involved. After these transactions, Mills directly beneficially owned 486,118 shares of REGENXBIO common stock.
REGENXBIO Inc. Chief Medical Officer Steve Pakola reported equity awards in the form of restricted stock units and stock options. On January 6, 2026, he received 65,847 shares of common stock underlying a time-based RSU grant at $0.00 per share, with 25% scheduled to vest on each of January 6, 2027, 2028, 2029 and 2030, contingent on continued service. He was also granted 35,402 stock options with a $14.18 exercise price, expiring on January 6, 2036; 25% of these options vest after 12 months of continuous service, and the remainder vest in equal monthly installments over the following 36 months starting after January 6, 2027. Following these grants, he directly beneficially owns 258,317 shares of common stock and 35,402 stock options.
REGENXBIO Inc. Chief Technology Officer Craig Malzahn reported new equity awards. On January 6, 2026, he was granted 65,847 shares of common stock for $0.00 per share, representing a restricted stock unit award. According to the terms, 25% of these RSUs will vest on each of January 6, 2027, January 6, 2028, January 6, 2029 and January 6, 2030, as long as he continues to provide service to the company.
After this grant, he beneficially owned 82,194 shares of common stock directly. He also received stock options to purchase 35,402 shares of common stock at an exercise price of $14.18 per share, expiring January 6, 2036. For this option, 25% of the shares will vest after 12 months of continuous service, with the remaining shares vesting in equal monthly installments over the 36 months following January 6, 2027.
REGENXBIO Inc. reported that Chief Executive Officer and director Simpson Curran received new equity awards on January 6, 2026. The filing shows a grant of 144,864 shares of common stock underlying a time-based restricted stock unit award at $0.00 per share, with 25% of the shares vesting on each of January 6, 2027, January 6, 2028, January 6, 2029, and January 6, 2030 while continuous service is maintained. After this grant, Curran directly beneficially owned 342,467 shares of common stock. The filing also reports an option grant for 233,651 stock options with an exercise price of $14.18 per share, expiring on January 6, 2036. Twenty‑five percent of these options vest after 12 months of continuous service with the remaining balance vesting in equal monthly installments over the 36 months following January 6, 2027.
REGENXBIO Inc.'s Chief Strategy & Legal Officer, Patrick J. Christmas, reported new equity awards. On January 6, 2026, he received 73,749 shares of common stock through a time-based restricted stock unit award at a price of $0.00 per share. According to the award terms, 25% of these RSUs will vest on each of January 6, 2027, 2028, 2029 and 2030, as long as he continues providing service to the company.
He was also granted stock options for 39,650 shares of common stock with an exercise price of $14.18 per share. These options vest 25% after 12 months of continuous service, with the remaining balance vesting in equal monthly installments over the 36 months following January 6, 2027, subject to continued service, and expire on January 6, 2036. After these transactions, he directly holds 215,367 shares of common stock and 39,650 stock options.
REGENXBIO Inc. reported that its Chief Financial Officer, Mitchell Chan, received new equity awards on January 6, 2026. He was granted 73,749 shares of common stock underlying a time-based restricted stock unit (RSU) award at a grant price of $0.00 per share. These RSUs vest in four equal installments of 25% each on January 6, 2027, January 6, 2028, January 6, 2029 and January 6, 2030, as long as he continues providing service to the company.
Chan also received 39,650 stock options with an exercise price of $14.18 per share, expiring on January 6, 2036. For this option grant, 25% of the shares vest after 12 months of continuous service, with the remaining 75% vesting in equal monthly installments over the 36 months following January 6, 2027. After these reported grants, he directly beneficially owned 127,717 shares of common stock and 39,650 stock options.
REGENXBIO Inc. Chief Strategy & Legal Officer Patrick J. Christmas reported a tax-related share withholding transaction. On January 2, 2026, 9,793 shares of REGENXBIO common stock were withheld at a price of $14.4 per share to cover taxes due upon the vesting of previously granted restricted stock units.
These restricted stock units were originally granted on January 3, 2022, January 3, 2023 and January 2, 2024. After this withholding, Christmas beneficially owned 141,618 shares of REGENXBIO common stock, held directly.